Medication info
Vildagliptin/Metformin Tablet 50/500 mg (Vildagliptin, Metformin)

Vildagliptin/Metformin Tablet 50/500 mg (Vildagliptin, Metformin)

Prescription medicationTablet
Ingredient · strength
Vildagliptin Hydrochloride›56mg / 1 tabletMetformin Hydrochloride›500mg / 1 tablet
Manufacturer / importer
Hanmi Pharmaceutical Co., Ltd.
Appearance
Bright yellow oval film-coated tablet
Packaging
30 tablets/bottle
Approval status
Active

MFDS item code 202105309 · Approved 2021.07.13 · Insurance code 643508420

Summary

Main use
Improvement of glycemic control in patients with type 2 diabetes mellitus
Who uses it
Adults
Adult dosage
For the treatment of patients with type 2 diabetes mellitus, the dose of this medicine should be individualized based on efficacy and tolerability, without exceeding vildagliptin 100mg and metformin 2000mg. A daily dose of vildagliptin greater than 100mg is not recommended. This medicine is generally administered with or immediately after a meal to reduce gastrointestinal adverse reactions caused by metformin. 1. Patients with no prior experience of antidiabetic drug therapy for whom adequate glycemic control cannot be achieved with monotherapy: The initial dose is 1 tablet of this medicine 50/500mg once daily. The dose may be gradually increased up to 1 tablet of 50/1000mg twice daily. 2. Patients switching from concomitant use of vildagliptin and metformin: Patients switching from concomitant use of vildagliptin and metformin to this medicine may start with the doses of vildagliptin and metformin they were previously taking. No studies have been conducted to evaluate the safety and efficacy of switching from other oral hypoglycemic agents to this medicine. Any change in the treatment regimen for type 2 diabetes mellitus may cause changes in glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. If you miss a dose of this medicine, take it with your next meal unless it is time to take the next dose. Do not take a double dose at one time to make up for a missed dose. Patients with hepatic impairment This medicine is not recommended for patients with clinical or laboratory evidence of hepatic impairment, including patients whose ALT or AST levels exceed 2.5 times the upper limit of normal, before starting treatment.

Ingredients

Manufacturer
Hanmi Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in patients with type 2 diabetes mellitus

View approved original text

This medication is used as a treatment to assist in blood sugar control in patients with type 2 diabetes by using vildagliptin and metformin together, in conjunction with dietary therapy and exercise therapy. This effectively improves blood sugar levels and supports diabetes management.

Dosage and Administration

Adult dosage

For the treatment of patients with type 2 diabetes mellitus, the dose of this medicine should be individualized based on efficacy and tolerability, without exceeding vildagliptin 100mg and metformin 2000mg. A daily dose of vildagliptin greater than 100mg is not recommended. This medicine is generally administered with or immediately after a meal to reduce gastrointestinal adverse reactions caused by metformin. 1. Patients with no prior experience of antidiabetic drug therapy for whom adequate glycemic control cannot be achieved with monotherapy: The initial dose is 1 tablet of this medicine 50/500mg once daily. The dose may be gradually increased up to 1 tablet of 50/1000mg twice daily. 2. Patients switching from concomitant use of vildagliptin and metformin: Patients switching from concomitant use of vildagliptin and metformin to this medicine may start with the doses of vildagliptin and metformin they were previously taking. No studies have been conducted to evaluate the safety and efficacy of switching from other oral hypoglycemic agents to this medicine. Any change in the treatment regimen for type 2 diabetes mellitus may cause changes in glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. If you miss a dose of this medicine, take it with your next meal unless it is time to take the next dose. Do not take a double dose at one time to make up for a missed dose. Patients with hepatic impairment This medicine is not recommended for patients with clinical or laboratory evidence of hepatic impairment, including patients whose ALT or AST levels exceed 2.5 times the upper limit of normal, before starting treatment.

Precautions

This medication may cause severe lactic acidosis or hypoglycemia, so caution is required. It should not be used in patients with moderate or severe renal impairment, heart failure, acute myocardial infarction, or sepsis. Prior to examinations using radiographic contrast agents, this medication should be stopped at least 48 hours beforehand, and should only be resumed after confirming normal kidney function post-examination. It should not be administered to individuals allergic to this medication or its components, type 1 diabetes patients, or patients with diabetic ketoacidosis. In cases of severe infections, trauma, or around surgery, it should be temporarily discontinued and resumed only after recovery. Caution is also necessary in patients with poor nutritional status, liver dysfunction, or those who consume excessive alcohol. Pregnant or breastfeeding women should not take this medication. Irregular meals, vigorous exercise, and interactions with other medications can increase the risk of hypoglycemia or lactic acidosis, so caution is advised. During treatment, headaches, dizziness, nausea, and hypoglycemic symptoms may occur; if symptoms are severe, consult a physician. If liver abnormalities are suspected, regular liver function tests should be conducted, and if abnormalities are found, medication should be discontinued. If renal function is impaired or concomitant drugs that may affect renal function are used, kidney function should be monitored frequently. If symptoms of acute pancreatitis appear, the medication should be stopped immediately and medical attention should be sought. In case of overdose, immediate medical treatment should be sought; blood dialysis may be helpful if necessary. The use of this medication is not recommended for children and adolescents under 18 years of age. Elderly patients may be at risk of decreased renal function, so dosage adjustments and monitoring of renal function are necessary. Alcohol may increase the risk of lactic acidosis, so drinking should be avoided while on this medication. Caution is advised when driving or operating machinery as dizziness or hypoglycemic symptoms may occur. Blood glucose and glycosylated hemoglobin levels should be regularly monitored to assess treatment effectiveness. Blood tests should be performed to check vitamin B12 levels, and appropriate action should be taken if abnormalities are found. If skin reactions such as blisters or ulcers occur during the course of this medication, inform a doctor immediately and seek treatment.

Side effects

  • Lactic acidosis
  • hypoglycemia
  • hepatitis
  • abnormal liver function
  • elevated transaminase levels
  • angioedema
  • tremors
  • headaches
  • dizziness
  • fatigue
Show 43 more
  • nausea
  • gastroesophageal reflux
  • diarrhea
  • bloating
  • chills
  • reduced blood sugar
  • asthenia
  • hyperhidrosis
  • constipation
  • arthralgia
  • upper respiratory tract infection
  • rhinitis
  • peripheral edema
  • dysphoria
  • vomiting
  • diarrhea
  • abdominal pain
  • loss of appetite
  • taste disorders
  • erythema
  • pruritus
  • urticaria
  • pancreatitis
  • blisters
  • exfoliative skin lesions
  • severe and disabling arthralgia
  • cutaneous vasculitis
  • cholecystitis
  • dyspepsia
  • abdominal discomfort
  • gastrointestinal abnormalities
  • increased serum amylase
  • increased lipase
  • bullous pemphigoid
  • myalgia
  • abnormal sensation
  • fever
  • edema
  • elevated creatine phosphokinase
  • elevated AST
  • increased C-reactive protein
  • elevated myoglobin levels
  • swelling of hands and feet

Not everyone experiences these, and they can vary from person to person.

Storage

This medication is sensitive to air and moisture; therefore, it should be stored in a tightly sealed container at room temperature between 1 and 30 degrees Celsius. This helps maintain the medication's efficacy and prevents degradation.

Appearance and packaging

Appearance

Bright yellow oval film-coated tablet

Package unit

30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.